NCT03125408 is a clinical trial of HCV Assay in Hepatitis C, sponsored by Beckman Coulter, Inc..

Who is sponsoring NCT03125408?

NCT03125408 is sponsored by Beckman Coulter, Inc..

What drugs are being tested in NCT03125408?

Interventions in NCT03125408: HCV Assay.

What condition does NCT03125408 study?

NCT03125408 studies Hepatitis C.

Is NCT03125408 still recruiting?

NCT03125408 is currently terminated. Last updated 12 July 2018.

Last reviewed 2018-07-12 · How we verify

NCT03125408

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Performance Evaluation of DxN HCV Assay

Terminated Last updated 12 July 2018

What this trial tests

trial testing HCV Assay in Hepatitis C in 210 participants. Terminated before completion.

Timeline

2 May 2012

Primary endpoint
30 August 2017

30 August 2017

Quick facts

Lead sponsor	Beckman Coulter, Inc.
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	210
Start date	2 May 2012
Primary completion	30 August 2017
Estimated completion	30 August 2017
Sites	1 location across United States

Drugs / interventions tested

HCV Assay

Conditions studied

Hepatitis C — all drugs for Hepatitis C →

Sponsor

Beckman Coulter, Inc.

Who can join

18 and older, any sex, with Hepatitis C. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The DxN Hepatitis C Virus (HCV) Assay is an in vitro diagnostic assay intended as an aid in the management of of HCV-infected individuals undergoing antiviral therapy. The purpose of the study is to establish the clinical performance of the DxN HCV Assay for plasma samples in the intended use population.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hepatitis C

Currently open trials in the same condition.

NCT06263829 — HCV Tappt Adherence Study · NA · recruiting
NCT06179498 — Partner Navigation Intervention for Hepatitis C Treatment Among Young People Who Inject Drugs · NA · recruiting
NCT06367465 — Feasibility and Acceptability of HCV Treatment in Pregnancy · recruiting
NCT05668780 — Buprenorphine Integration Research and Community Health · NA · active not recruiting
NCT05208697 — Tele-Harm Reduction · NA · active not recruiting

Other Beckman Coulter, Inc. trials

Trials by the same sponsor.

NCT07217431 — Access BNP Clinical Performance Evaluation: Testing and Clinical Concordance Study · completed
NCT06624293 — Access BNP Clinical Enrollment Study · completed
NCT06379061 — Access MeMed BV Assay Clinical Study Collection Protocol - Infectious Adult and Pediatric Cohorts · completed
NCT06289868 — Access Anti-HAV and Access Anti-HAV IgM Assays EU Clinical Trial Protocol (HAV-EU-11-23) · completed
NCT06257628 — MACE CDS Software Master Enrollment Protocol · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03125408 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beckman Coulter, Inc.
Last refreshed: 12 July 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03125408.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing